Enliven Therapeutics (NASDAQ:ELVN) just reported results for the fourth quarter of 2023.
- Enliven Therapeutics reported earnings per share of -47 cents. This was above the analyst estimate for EPS of -54 cents.
- The company did not report any revenue for the quarter.